XXI World Allergy Congress on 06-10 December 2009 in Buenos Aires, Argentina is coming up soon.
For more information, please visit the official website:
Members of EAMG support the educational activities during the annual meeting of the European Academy of Allergy and Clinical Immunology with several symposia focusing on the potential and benefits of allergen specific immunotherapy. During symposia arranged by members of EAMG the latest products and treatment concepts for administration of allergen vaccines are discussed.
The following symposia are planned for the next EAACI meeting:
Sunday 7th June, 17:30
Satellite Symposium - ALK-Abelló
Innovative Approaches to Optimisation of Subcutaneous Immunotherapy
Chairperson:
Stephen Durham, United Kingdom
Understanding intact allergens - does nature know best?
Moises Calderon, United Kingdom
Understanding allergoids - improving on nature's design
Harald Renz, Germany
Understanding recombinant allergens - diagnosis and therapy of tomorrow?
Marianne van Hage, Sweden
Developments in specific immunotherapy - future directions and new opportunities
Henrik Jacobi, Denmark
Monday 8th June, 10:30
Company Sponsored Symposium – Allergopharma
The Growing Problem of Allergic Airway Disease - Aetiology and the Potential of Causal Treatment (SIT)
Chairpersons:
Marek Jutel, Poland
Gianni Marone, Italy
Allergic inflammation in the airways
Carsten Schmidt-Weber, United Kingdom
Modulation of allergic inflammation with specific immunotherapy
Sabina Rak, Sweden
Role of immunotherapy in asthma prevention and management
Christian Virchow, Germany
Aspects for therapeutic decisions in allergy
Gerard Schultze-Werninghaus, Germany
Monday 8th June, 10:30
Company Sponsored Symposium - ALK-Abellò
The management of united airways with tablet-based immunotherapy - evidence of curative effect?
Chairperson:
Glenis Scadding, United Kingdom
Allergic rhinitis is not a trivial disease - need for tablet-based immunotherapy?
Erkka Valovirta, Finland
Disease modifying effect of tablet-based immunotherapy - will this change our medical practice?
Stephen Durham, United Kingdom
House dust mite tablet-based immunotherapy in asthma - clinical proof of concept
Vibeke Backer, Germany
Does tablet-based immunotherapy address the needs of our patients?
Anthony Frew, United Kingdom
Tuesday 9th June, 10:30
Company Sponsored Symposium – Stallergenes
Efficacy in SIT to Grass Pollen: the Meeting of "Evidence"
Chairpersons:
Karl-Christian Bergmann, Germany
Piotr Kuna, Poland
Pharmacodynamics of a sublingual desensitisation tablet: onset of action and clinical efficacy
Olivier de Beaumont, France
The grass pollen SLIT tablet: the EBM benchmark in SIT
Ulrich Wahn, Germany
SIT efficacy: evaluation of the therapeutic effect
Hans-Jørgen Malling, Denmark
|